GHK-Cu is the rare gray-market peptide with a genuinely deep research record - hundreds of publications since the 1970s - and a mainstream, legal use: it has been in cosmetic serums for decades. The 2026 surge of interest is about injectable forms, where the evidence is thinner and the regulatory status flips. This guide separates the three questions people collapse into one: what the molecule does, which form the evidence supports, and what is actually legal.
What GHK-Cu is
GHK-Cu is a tripeptide - glycyl-histidyl-lysine - bound to a copper ion. It occurs naturally in human plasma, saliva, and urine, and its concentration declines with age (roughly 200 ng/ml at age 20 to 80 ng/ml by age 60 in frequently cited plasma data). That decline is the origin of the anti-aging narrative.
Mechanistically, published work associates GHK-Cu with collagen and glycosaminoglycan synthesis, modulation of metalloproteinases, angiogenesis, and antioxidant enzyme activity - a wound-remodeling profile, which is why the strongest research sits in dermatology and wound care.
Where the evidence is strong - and where it isn't
| Use | Form studied | Evidence level |
|---|---|---|
| Skin appearance (fine lines, firmness) | Topical creams/serums | Multiple small controlled human studies |
| Wound healing support | Topical / dressing | Human and animal studies |
| Hair growth support | Topical | Small studies, suggestive |
| Systemic 'regeneration', longevity | Injectable | Preclinical only - no human trials |
The pattern matters: virtually all human evidence involves topical application. Injectable GHK-Cu - the form driving current search interest - has no published human clinical trials behind it. Anyone claiming otherwise is extrapolating from cell and animal work.
Topical vs injectable: the legal line
- Topical cosmetic GHK-Cu is legal, mainstream, and sold by major skincare brands. Cosmetics don't require FDA pre-approval (they must simply not make drug claims).
- Injectable GHK-Cu is an unapproved drug with no legal compounding pathway. Vials are sold under research-use-only labels - a seller posture, not a buyer permission.
- The same molecule, two regulatory universes. The form decides the law.
The dosage math (and why GHK-Cu numbers look strange)
GHK-Cu circulates in milligram quantities - vials of 50 mg or 100 mg are typical, versus 5-10 mg for most peptides. Amounts discussed in gray-market use are often 1-2 mg, a thousand times the microgram amounts common for compounds like BPC-157. If you're converting vial contents to syringe units, the arithmetic is identical to any peptide: concentration = mg ÷ ml of bacteriostatic water; volume = amount ÷ concentration; units = volume × 100.
A worked example: a 50 mg vial with 5 ml of water is 10 mg/ml. A 1 mg draw is 0.1 ml - 10 units on any U-100 syringe. Our GHK-Cu calculator runs this with your actual numbers and flags draws that are too small or too large to measure reliably.
Safety profile and unknowns
- Topical use has decades of cosmetic history with low reported irritation rates.
- Injectable use has no systematic human safety data - that is the honest, complete answer.
- Copper handling is a real consideration: GHK's biology is copper biology, and systemic copper excess has known toxicity. No one has published what chronic injected GHK-Cu does to copper homeostasis in humans.
- Product quality is the dominant practical risk: research-chemical vials carry no verified identity, sterility, or purity.
Quality markers: the blue test and what it can't tell you
GHK-Cu has a built-in first-pass authenticity check most peptides lack: the copper-peptide complex is intensely blue. Genuine GHK-Cu powder is blue-violet, and a reconstituted solution is a clear sky blue whose depth tracks concentration. A colorless vial sold as GHK-Cu is either copper-free GHK (a different, cheaper product) or not GHK at all.
The limits of the test cut the other way: blue proves copper, not purity. Copper sulfate is also blue and costs nothing. So the color rules products out but never rules them in - identity and purity still require a lot-specific COA with HPLC and mass-spec data, the same standard as any research chemical. In cosmetics, the same logic applies to 'copper peptide' serums that are conspicuously colorless at claimed high concentrations.
Frequently asked questions
Is GHK-Cu FDA approved?
No form of GHK-Cu is an FDA-approved drug. Topical cosmetic use is legal because cosmetics don't require approval; injectable GHK-Cu is an unapproved drug with no legal compounding pathway.
Does topical GHK-Cu work?
Small controlled human studies report improvements in skin firmness, fine lines, and photoaging markers versus placebo vehicles. Effects are modest and formulation-dependent - the honest summary is 'evidence-supported cosmetic ingredient', not 'clinical rejuvenation'.
What's a typical GHK-Cu dosage?
There is no established human dosage for injectable GHK-Cu because there are no human trials - anything you read is extrapolation. Topical products typically contain 0.05-3% concentrations. For vial math (mg to syringe units), use the calculator; it converts, it doesn't recommend.
Why is GHK-Cu blue?
The blue color is the copper - the GHK-copper complex absorbs red light, so powder and solutions appear blue, deeper with concentration. It's a useful authenticity screen (colorless 'GHK-Cu' lacks copper) but not a purity test: copper sulfate is blue too. Identity still requires lab analysis.